Lunai Bioworks Inc(LNAI) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -61.29 | Insider Own | 44.4% | Shs Outstand | 4.5M | Perf Week | -1.38% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 2.5M | Perf Month | 0.47% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | - | Inst Own | 4.33% | Short Float | 6.92% | Perf Quarter | -37.61% |
| Income | -0.13B | P/S | 485.1 | EPS this Y | - | Inst Trans | 7.8% | Short Ratio | 0.9 | Perf Half Y | -26.71% |
| Sales | 0.00B | P/B | - | EPS next 5Y | - | ROA | -201.09% | Short Interest | 0.17M | Perf YTD | -69.66% |
| Book/sh | -2.14 | P/C | 3.07 | EPS past 3/5Y | 20.66% -34.35% | ROE | -325.46% | 52W High | -85.1% ($14.36) | Perf Year | -83.63% |
| Cash/sh | 0.7 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 76.8% ($1.21) | Perf 3Y | -99.31% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -63.58% | Gross Margin | -360.71% | Volatility(W/M) | 10.66% 9.97% | Perf 5Y | -99.63% |
| Dividend TTM | - | EV/Sales | 397.6 | Sales Y/Y TTM | - | Oper. Margin | -46991.98% | ATR (14) | 0.24 | Perf 10Y | -98.66% |
| Dividend Ex-Date | - | Quick Ratio | 0.19 | EPS Q/Q | -994.57% | Profit Margin | -612568.11% | RSI (14) | 42.15 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.19 | Sales Q/Q | - | SMA20 | -7.99% ($2.33) | Beta | 0.31 | Target Price | - |
| Payout | - | Debt/Eq | - | Earnings | - | SMA50 | -8.96% ($2.35) | Rel Volume | 0.27 | Prev Close | $2.23 |
| Employees | 29 | LT Debt/Eq | - | EPS/Sales Surpr. | - | SMA200 | -44.43% ($3.85) | Avg Volume(3M) | 0.19M | Price | $2.14 |
| IPO | 2015/2/2 | Option/Short | No/Yes | Trades | 369 | Volume | 52,049 | Change | -4.04% |
Company
LNAI is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🤖 Lunai BioWorks () is an AI biotech that combines AI, phenomics, and biological models to accelerate new drug target discovery and the development of chemical defense and central nervous system (CNS) therapeutics. The company is advancing multiple programs targeting CNS diseases such as Alzheimer's, alcohol use disorder, and chemical/biological defense responses, and also operates a U.S. defense-related consortium through its subsidiary BioSymetrics.
Over the past 1 year, on the lower side
85% below its 1-year high.
LNAI has weak earning power
-46991.98% of revenue is kept as operating profit.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Holding long would have lost money
Would have changed by -99.3% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 4.3%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
VTI 0.00%
VXF 0.00%It ranks #4 in the industry
Based on market cap of $10M.
LNAI $10M PER -
VRTX $131B PER 30.0
REGN $83B PER 19.8
MRNA $73B PER -
FAQ
What kind of company is LNAI?
LNAI belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of LNAI?
The market cap of LNAI is approximately $10M, ranking 5,520 within its sector.
What is the 52-week high and low for LNAI?
LNAI has recorded a 52-week high of $14.36 and a low of $1.21.
